Non-responders, and the honest state of the evidence about them
The mechanism is well described. The variance is not.
Archive — 2024
Volume I: 12 issues, 2,040 pieces.
Mexico pharmacy body issues counselling standards for semaglutide initiation
The evidence base is thin and the document says so, which is to its credit.
What changed at CPC in December, and what the company will not say about it
Documentation practice is the only part of vendor quality a buyer can assess before purchase.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
The arithmetic behind every identity confirmation, worked in full
A peptide has a monoisotopic mass and an average mass, they differ by several daltons at this molecular size, and a certificate that does not say which it quotes cannot be…
What we would need to measure to explain the response distribution
The mechanism is well described. The variance is not.
The 16-day notice: how a compounding wind-down works in New Zealand
The document is four pages. Three of them are about dates.
Guangzhou export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
France health authority warns on falsified dulaglutide pens
Reported from the analysis, not from a warning notice.
The consolidator trading as Meridian Freight Partners enters a consent decree and stops sterile preparation
The observation that closes a facility is rarely the dramatic one.
Gallstones during rapid weight loss: drug, or weight loss?
We give background rates alongside trial rates, because an event occurring during treatment is not thereby caused by it.
Two-thirds back: the extension nobody expected to be the headline
A withdrawal trial answers a narrower question than it appears to. This piece states which question.
Mexico caps semaglutide prescribing to 21 specialist centres
Efficacy was never the question in this appraisal. Duration of treatment was.
What a 27% rise in coupling-reagent prices does to a 5 mg vial
Follow the resin, not the catalogue.
Holograms, QR codes and other things that are not verification
Reported from the analysis, not from a warning notice.
From the floor in Xi'an: 22 posters, one theme
Reported from the sessions, and from the two hours afterwards.
Why FGP can be entirely straightforward and still tell you nothing about bioburden
The Journal has read several hundred certificates from twenty companies. We set out what the documents actually cover, and what a reader is filling in from imagination.
Load, not cardio: the distinction the general advice keeps losing
The older-adult diet-and-exercise trials are the closest analogue to rapid pharmacological weight loss, and they are twenty years old.
The quiet end of Calder Vale Peptides of Skipton
A proper account of an operation that existed, and of what closing it cost.
Switzerland pharmacy body issues counselling standards for exenatide initiation
The evidence base is thin and the document says so, which is to its credit.
SURMOUNT-3 extension data: what happens after the trial stops
A design note rather than a result: what the comparator was, and what that permits you to conclude.
Why a dead-clean sterile filter can pass pyrogen straight through
The limit for a parenteral product is calculable from the dose and the body weight in two lines. Almost nobody in this trade performs the calculation.
The pyrogen question has a price, and it is not the price of a purity run
Endotoxin is the more tractable of the two questions, and a kinetic chromogenic determination is neither slow nor exotic. It is simply not on the menu.
Why "muscle-sparing" is a marketing term and not a measurement
Almost every practical recommendation in circulation was established in a population that does not resemble the people now following it.
Inspectors cite Halvard & Pike Apothecary of Portland, Maine over sterility assurance
The observation that closes a facility is rarely the dramatic one.
What the new Portugal guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Nantong export categories for peptide intermediates were quietly renamed
Follow the resin, not the catalogue.
Germany declines to reimburse tirzepatide outside a specialist service
Efficacy was never the question in this appraisal. Duration of treatment was.
Three weeks off is a fresh start, whether or not you want one
Concentrations fall by half a week, so a month away leaves a small fraction of steady state. Resuming at the previous dose presents the receptor with a step it has not seen…
The 16-day notice: how a compounding wind-down works in Australia
The document is four pages. Three of them are about dates.